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Abstract 
Background: PMBT constitute less than 2% of all malignancies and carry a dismal prognosis. 
Treatment options at relapse are limited. First-in-human solid tumour studies have historically excluded 
patients with PMBT due to the poor prognosis, concomitant drug interactions and concerns regarding 
toxicities.  
 
Methods: Retrospective data were collected on clinical and tumour characteristics of patients referred 
for consideration of Ph1 trials in the Royal Marsden Hospital (RMH) between June 2004 and August 
2016. Survival analyses were performed using the Kaplan-Meier method, Cox proportional hazards 
model. Chi-squared test was used to measure bivariate associations between categorical variables.  
 
Results: 100pts with advanced PMBT were referred. At initial consultation, patients had a median 
ECOG PS 1, median age 48 years (range 18-70); 69% were men, 76% had glioblastoma; 68% were on 
AEDs, 63% required steroid therapy; median number of prior treatments was 2. Median OS for patients 
treated on a Ph1 trials was 9.3 mo(95% CI: 5.9-12.9) vs. 5.3 mo(95% CI 4.1-6.1) for patients that did 
not proceed with a Ph1 trial, p=0.0094. Steroid use, poor PS, neutrophil-to-lymphocyte ratio and 
treatment on a Ph1 trial were shown to independently influence OS.  
 
Conclusions: We report a survival benefit for patients with PMBT treated on Ph1 trials. Toxicity and 
efficacy outcomes were comparable to the general Ph1 population. In the absence of an internationally 
recognized standard second line treatment for patients with recurrent PMBT, more Ph1 trials should 
allow enrolment of patients with refractory PMBT and Ph1 trial participation should be considered at 
an earlier stage. 
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Background 
Primary malignant brain tumours (PMBT) are a rare tumour group, constituting less than 2% of all 
malignancies, and carry a dismal prognosis[1], [2]. Despite recent incremental gains and therapeutic 
advances, including the emerging understanding of underlying genetic alterations, these tumors remain 
incurable and invariably recur.  Treatment options at relapse remain limited.   
 
The primary objectives of first-in-human solid tumor studies are to determine the safety, toxicity, 
maximum-tolerated dose (MTD), preliminary efficacy, and recommended dosing of novel agents for 
phase II and III studies[3] and efficacy data are now increasingly used to look for a signal in particular 
tumors.  Phase I studies use strict eligibility criteria and have historically excluded patients with PMBT 
such as glioblastoma[4], [5] due to a number of concerns, including poor prognosis, concomitant drug 
interactions, concerns about excessive toxicities and limited efficacy as a result of poor penetration 
across the blood-brain barrier[4], [5].  Such concerns of course, are less relevant in the molecular era, 
and we suggest that the reasons for excluding these patients are largely archaic. 
We conducted a retrospective analysis of our experience of patients with PMBT referred for 
consideration of Phase I trials in the Royal Marsden Hospital, and analyzed baseline patient 
characteristics and organ function, toxicities, responses, and survival. 
 
Patients and Methods 
This retrospective study considered consecutive patients with PMBT referred for consideration of 
Phase I trials in the Royal Marsden Hospital between June 2004 and August 2016.  We defined patients 
with PMBT as patients with grade III or above malignant intracranial neoplasms involving the brain.  
Phase I trials of molecular agents and/or single-agent cytotoxic for which complete data were available 
were included. Molecular agents are defined as drugs that target an extra- or intracellular mechanism 
different from those associated with conventional chemotherapy such as DNA, tubulin, or cell division 
machinery. Eligible patients were ≥18 years of age with histologically proven PMBT. All patients had 
recurrent PMBT and had received at least one line of prior treatment. 
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The following patient and laboratory characteristics were reviewed: age at diagnosis, sex, Eastern 
Cooperative Oncology Group (ECOG) performance status, prior surgery, prior radiation therapy, prior 
chemotherapies, tumour location, class of investigational agent, and baseline laboratory evaluations 
including neutrophil to lymphocyte ratio (NLR) at the first clinic appointment and at screening. RMH 
score at the first clinic appointment and at screening was also assessed; (the RMH score  is derived 
from the  albumin value, the lactate dehydrogenase value, and the number of metastatic sites). It has 
been developed  as a predictive factor of  patient survival in phase I trials, and has been validated as a 
predictor of survival in large numbers of patients with lung, pancreatic, and head and neck tumors 
treated on phase I trials [6].  Where possible, tumor molecular data including MGMT status, 1p19q 
status, IDH-1 mutation status was collected.  In addition, the type of concurrent antiepileptic drug 
(enzyme inducing versus non enzyme inducing) and steroid use was documented. All drug-related 
serious adverse events (SAEs) were recorded, and toxicities were graded using Common Terminology 
Criteria for Adverse Events (CTCAE version 4.0).  The study proposal was reviewed and passed by the 
ethics committee at the Royal Marsden hospital. 
 
 
Statistics  
Patient characteristics were summarized using means and standard deviations (SD), or medians and 
ranges if the data were continuous and normally or non-normally distributed, respectively. The Chi-
squared test was used to measure bi-variate associations between categorical variables, respectively. 
Median survival was estimated using Kaplan Meier methods, and the log rank test was used to establish 
group differences. Cox proportional hazards modeling was used to examine the associations between 
survival and clinically relevant prognostic factors thought to influence outcome. Hazard ratios and their 
95% confidence intervals were estimated and presented. Statistical significance levels were set at 5% 
for all tests carried out. 
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Results  
Patients and Trial Characteristics 
A total of 100 patients were referred for consideration of participation in a phase I trial from 2004 to 
2016 (Table 1).  The median age was 48 years (range, 18 to 70 years) with a median Eastern 
Cooperative Oncology Group performance status of 1 (range, 0 to 3). All patients had a diagnosis of 
recurrent refractory PMBT and had received at least one line of prior treatment; 76% (n=76) had 
glioblastoma. The median number of prior chemotherapies was two (1-5), with temozolomide the first-
line treatment in 76% of 100 patients. Ninety-two percent of patients received prior radiation therapy as 
part of initial management of PMBT; while data on prior treatments were missing for five patients 
(5%).  Sixty-eight percent of all patients seen in clinic for an initial consultation (n=68) were on 
treatment with at least one antiepileptic drug (AED). Data were unavailable for seven patients (7%); 
31% were taking enzyme-inducing AEDs (EIAEDs), and 18% of patients were on two or more AEDs.  
Sixty-three percent of all patients required steroid therapy on first assessment. Sixteen percent of all 
patients had a documented co-morbidity.  
 
With regards to patient allocation, fifty-nine percent of patients were allocated to a phase I trial (n=59); 
forty-two patients (42%) went on to receive investigational agent in a phase I trial (Figure 1); classes of 
compounds are shown in Table 2. Of the patients allocated to a phase I trial, but were unable to go on 
to receive drug, six patients failed screening, three patients declined treatment, seven patients 
underwent rapid deterioration following initial review or there was no suitable trial available (n=1); 
data were unavailable for one patient.  The most common reason for the patients who were not 
allocated to a trial was lack of suitable trials available at the time  (n=20).  Fourteen percent of patients 
(n=14) were not allocated due to poor performance status / deemed unsuitable for phase I trial 
participation. Five percent (n=5) of patients were not interested in participating in a phase I trial. 
 
 
Toxicities 
Thirty-seven of the total forty-two patients treated on a phase I trial demonstrated drug-related 
toxicities of various grades; five patients had no drug-related adverse events. The majority of 
investigational agents, with or without the addition of chemotherapy, were well-tolerated, with minimal 
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side effects, and patterns similar to many molecularly targeted treatments.  Of note, these toxicities 
were typically in the grade 1 category.  All toxicities were assessed according to the CTCAE v 4.0 set. 
The most common drug related adverse events documented were grade 1 diarrhoea, with thirteen 
events (33%), nine events (21%) of grade 1 fatigue, eight events (19%) of grade 1 nausea; seven events 
of grade 1 rash (17%) and six events (14%) of grade 1 transaminitis were noted, while the most 
common grade 2 toxicities observed were fatigue with five events (12%) and nausea with four events 
(9%). There were two grade 4 toxicities, hyponatraemia (2%) and creatinine kinase elevation (2%); 
there were no grade 5 toxicities.  There were no study related deaths.  Table 3 shows a detailed 
description of events and grading of drug related toxicities observed in the population studied.  
 
Twenty-seven patients were receiving AEDs during their participation on a phase I trial, while twenty-
four were on steroids. The incidence of grade 1 diarrhoea was markedly higher in the group of patients 
on AEDs (26%) compared with those patients not taking AEDs (7%) but there was no difference in 
more severe grade  diarrhoea, or  in any other toxicities. There was also no significant difference in 
toxicity prevalence in the group of patients using steroids compared with those patients not receiving 
steroids. Table 3 demonstrates a detailed description of the toxicities seen in these two groups.  Of 
those patients treated on study, reasons for study discontinuation included disease progression (88%, 
n=37), drug toxicity (5%, n=2), patient withdrawal (5%, n=2), and other causes (2%, n=1). 
 
Survival 
There was no statistically significant difference in median progression-free survival (PFS) between 
patients (n=41) treated on a phase I trial (3.4 months, 95% CI: 2.7-4.7), and those patients (n=56) who 
did not proceed with treatment on a phase I trial (5.3 months, 95% CI: 4.1-6.1; P=0.1356), respectively 
(Figure 2).  However, there was a statistically significant difference in overall survival (OS) between 
the two groups.  Median OS for patients treated on a phase I trials was 9.3 months (95% CI: 5.9-12.9) 
vs. 5.3 months (95% CI 4.1-6.1) for patients that did not proceed with a phase I trial, P=0.0094, 
respectively (Figure 2). 
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Factors influencing survival 
Factors with a potential influence upon survival were examined using univariate and multivariate 
models, respectively.  The statistically significant factors that were shown to independently influence 
overall survival were steroid use, poor performance status, neutrophil-to-lymphocyte ratio (NLR), 
RMH prognostic score and treatment on a phase I trial.  The use of steroids was associated with shorter 
overall survival in both univariate (HR 2.33, 95% CI 1.44-3.77, p=0.001) and multivariate analysis 
(HR 1.84, 95% CI: 1.05-3.24, p=0.034; Figure 3), an association which was repeated when examining 
progression-free survival (HR 1.93, 95% CI: 1.21-3.06, p=0.005) (Table 4,5).  Perhaps unsurprisingly, 
poor performance status (ECOG PS 2/3) was also predictive of poorer outcomes, in both univariate and 
multivariate models (HR 16.01, 95% CI: 3.12-83.26, p=0.001; HR 44.9, 95% CI: 5.95-338.58, 
p=0.000) (Table 4,5).  
 
NLR was also examined; An elevated NLR ≥4 proved significant for survival and was associated 
independently with poorer outcomes in all models (Table 4,5; OS, multivariate analysis: HR 1.73, 95% 
CI 1.02-2.94, p-value 0.043). Patients with NLR≥4 were more likely to require steroids compared to 
patients with an NLR<4 (81% vs 38%). Use of steroids did not modify the association between NLR 
and outcomes, as patients with an elevated NLR≥4 and requiring steroids had the poorest outcome (p 
= 0.0364).  Median OS for patients with NLR≥4 on steroids was 4.1month (SE 0.29, 95% CI 3.29-
5.42), vs 19months median OS for patients not taking steroids (SE 8.61 95% CI.36-not reached)[Figure 
3]. 
 
The RMH score is calculated with albumin value, lactate dehydrogenase value, and the number of 
metastatic sites to predict patient survival in phase I trials. RMH score 0-1 was an independent variable 
that predicted survival in multivariate analysis (HR 0.48, 95% CI:0.25-0.90, p=0.023; Table 5). 
 
Patients receiving an investigational agent, with or without combination of other agents or 
chemotherapy, in the context of a phase I trial performed better than those patients who were not 
treated (HR 0.59, 95% CI 0.35- 0.99, p=0.048), with the patients participating in a phase I trial 
displaying an almost double likelihood of improved overall survival (Table 5).  Other factors that were 
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analysed such as age, sex, use of AEDs, and tumour location and laterality, however these did not 
provide any statistical significance relating to outcomes. 
 
Discussion 
In the United States, the annual incidence rate of primary CNS tumours in adults is 27.86 per 100,000, 
with gliomas accounting for 65% of malignant tumors[2].  With the advent of targeted therapies in this 
era of precision medicine, treatment of other solid tumors has dramatically changed in the past decade, 
while progress in the management of malignant brain tumours has disappointingly trailed behind.  For 
patients with recurrent PMBT, there are few active treatments approved, and as such these patients 
have limited treatment options. The Cancer Genome Atlas (TCGA) data have demonstrated a wide 
range of mutations involved in glioblastoma that could potentially be targeted by novel drugs[7].  
However, patients with PMBT are frequently unable to gain access to most phase I clinical trials under 
current eligibility criteria[4], [5], [8]. 
We report a significant survival benefit for patients with PMBT treated on Phase I trials.  This survival 
benefit may perhaps be due to the novel investigational agents these patients received while on phase I 
trials.  Traditionally, the majority of phase I trials of novel agents in oncology have excluded patients 
with PMBT due to a number of concerns.  These include poor prognosis, poor performance status, fear 
of excessive CNS toxicities, concomitant drug interactions, and limited efficacy as a result of poor 
penetration across the blood-brain barrier[4], [5].   Our data further confirm that patients with PMBT 
who meet standard strict phase I eligibility criteria and are enrolled onto trials of appropriately chosen 
compounds, successfully meet phase I end points, such as safety and toxicity.  Based on our results, 
these patients tolerate investigational agents similarly to other groups. We have demonstrated that the 
use of steroids does not affect the incidence of toxicities. The use of AEDs, however did increase the 
prevalence of a single toxicity.  Inherent selection bias of course, could contribute to the survival 
benefit noted.  Patients treated on trial could be selected as they appear healthier and they may live 
longer, which may or may not be due to treatment effect on outcome.  Indeed, from our dataset, 
patients with ECOG performance status 1 had better reported survival regardless of their participation 
on a phase I trial.  Nonetheless, this selection bias does not detract from our conclusion, that patients 
with PMBT can be enrolled and treated safely the Phase I setting.  To the best of our knowledge, this is 
the first single-centre published experience of patients with PMBT treated in the Phase I setting.  
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In our opinion, historical reasons for excluding patients with brain tumors from phase I trials are no 
longer valid.  As demonstrated in our cohort, patients with PMBT included on clinical trials tend to 
have few co-morbidities, are typically relatively young (the median age of glioblastoma trial patients 
55 is years), have usually received fewer lines of prior systemic treatments and tend to have no 
systemic metastases, without the compromise in organ function seen in patients with systemic 
metastatic disease.  Furthermore, patients with recurrent glioblastoma with reasonable performance 
status typically have a life expectancy of 4 to 7 months[9], [10], which is comparable to the expected 
survival of patients with other solid tumors included on phase I trials.  Our results further demonstrate 
that select patients with PMBT who meet standard phase I eligibility criteria have comparable fitness 
and organ function as their solid tumor counterparts, disproving the old belief that the performance 
status of patients with PMBT is too poor for participation in phase I studies. 
With regards to antiepileptic drugs (AEDs), historically patients with PMBT would have been treated 
with cytochrome P450 enzyme-inducing antiepileptic drugs (EIAEDs), such as carbamazepine[11].  
Increasingly however, there has been a trend in neuro-oncology towards the use of safer second and 
third generation non-EIADs such as levetiracetam and lamotrigine, drugs cleared through the kidney, 
with no CYP450 enzyme interaction.  Indeed, prophylactic AEDs are no longer recommended[12], and 
the majority of patients who require AEDs, including patients in our cohort, are treated with non-
EIAEDs, thus removing the potential for concomitant drug interactions.  
The frequent use of corticosteroids in patients with PMBT is another argument used to exclude these 
patients from phase I trials.  Corticosteroids, such as dexamethasone, are relatively weak inducers of 
CYP450 enzymes, however there are data confirming effect of corticosteroids on drug exposure is 
minimal, and they have little effect on the exposure or safety profile of drugs like irinotecan in high-
grade glioma and bortezomib in patients with myeloma or lymphoma[12], [13].  Our data revealed 
patients on corticosteroids suffered with poorer survival regardless of whether or not they proceeded 
with a phase I trial.  High-dose steroids are frequently used to control peri-tumoural oedema in 
glioblastoma patients, and can result in metabolic complications, such as hyperglycemia, obesity and 
type 2 diabetes.  These metabolic complications are associated with increased cancer risk and poor 
outcomes in cancer patients[14], and indeed a number of studies suggest that glioblastoma patients 
affected by these metabolic complications have worse prognosis compared with those with normal 
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metabolic conditions[15]–[17].  Consequently, we would advocate for reducing corticosteroid-use in 
brain tumour patients when possible. 
 
We have demonstrated in our cohort of the patients treated with investigational agents, alone or in 
combination with other agents or chemotherapies, that the toxicities encountered do not hinder quality 
of life.  Most events described were grade 1 and grade 2 events (Table 3), while the grade 3 and grade 4 
events in our cohort were significantly less than the general population treated on phase 1 trials.  
Historically, grade 3 and 4 toxicity rates for single-agent and combination phase I studies are estimated 
to range from 10.3% to 36%[18], [19].  More recently, there are data reporting grade 3 and 4 toxicity 
rates during cycle 1 of 14.1% and 1.9%, respectively, with single-agent molecular drugs[20].  Our 
cohort of patients demonstrated a maximum of 10% in grade 3 toxicities and a maximum of 2% of 
grade 4 drug related toxicities. There were no drug-related deaths, nor deaths on trial, irrespective of 
cause. Furthermore, it is noteworthy that there were no toxicity-related trial withdrawals.  Our toxicity 
outcomes are comparable to the general phase I patient population. 
 
Neutrophil-lymphocyte ratio (NLR) is a marker of systemic inflammatory response, and elevated levels 
have been associated with aggressive disease and poorer outcome in multiple tumour streams, 
including prostate, lung and colon cancer[21]–[25]. In patients with GBM, there are published data that 
elevated NLR prior to any initial therapy, including surgery or corticosteroids, is predictive for worse 
outcomes[26].  In our population of patients with recurrent PMBT, elevated NLR≥4 remained an 
independent prognostic indicator for poor outcome, independent of corticosteroid use. In our cohort, 
patients with elevated NLR >4 requiring steroids also demonstrated the worst outcomes – a reminder of 
the potential relevance of host immunity in malignant brain tumours. Given the ease and reduced cost 
of NLR testing, we hypothesize that NLR testing could prove to be a useful addition in predicting 
prognosis in PMBT patients.  
 
The RMH score uses albumin (≥3.5 g/dL vs <3.5 g/dL), lactate dehydrogenase (less than or equal to 
the upper limit of normal [≤ULN] vs >ULN), and the number of metastatic sites (≤2 sites vs ≥3 sites) 
to predict patient survival in phase I trials, and has been validated as a predictor of survival in large 
number of patients with lung, pancreatic, and head and neck tumours treated on phase I trials [6]. 
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Somewhat surprisingly, given the lack of systemic metastases of PMBT, in our population, RMH score 
0-1 was an independent variable that predicted survival in multivariate analysis, suggesting a possible 
prognostic role for the RMH score in this patient population.  While the RMH score has been validated 
in patients with solid tumours treated on Phase I trials, it has not yet been validated in patients with 
PMBT.  Serum albumin level however, is thought to be a reliable and convenient marker of the 
nutritional status in patients, and has previously been identified as a prognostic marker in high grade 
glioma[27].  Thus, it is conceivable that, lactate dehydrogenase levels are also of some significance in 
this patient population.  Given that systemic metastases are rare in this patient population, perhaps an 
adjusted-RMH score could have a prognostic role in this patient population.   
 
Regarding barriers to phase I enrolment, a lack of suitable trials remains a significant barrier, however 
this is similar to other rare malignancies.  We acknowledge there are a number of limitations in our 
study; most notably, our small sample size, and inclusion of both single agent and combination studies. 
Nonetheless, our study adds to the growing body of evidence encouraging investigators to enrol 
patients with PMBT in Phase I trials.   
 
Finally, in the absence of an internationally recognized standard second line treatment for patients with 
recurrent primary malignant CNS tumours, more phase I trials should allow enrolment of this patient 
population, and more brain tumour-specific trials with relevant eligibility criteria should be designed, 
encouraging phase I trial participation at an earlier stage. 
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CONSORT	diagram	showing	all	patients	with	PMBT	retrospectively	included	in	study.	
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Figure	2.	Kaplan	–Meier	curve	of	PFS	(A)	and	OS	(B)	of	pa=ents	with	PBMT	considered	for	phase	I	trials	 in	
Royal	Marsden	Hospital	between	2004	and	2016.	A:	No	sta=s=cally	 signiﬁcant	diﬀerence	was	 seen	 in	 the	
median	PFS	between	pa=ents	(n=41)	treated	(3.4	months,	95%	CI:	2.7-4.7)and	those	not	treated	(n=56)	on	a	
phase	I	trial	(5.3	months,	95%	CI:	4.1-6.1;	p=01356).	B:	Sta=s=cally	signiﬁcant	diﬀerence	in	the	median	OS	
was	seen	between	the	two	groups	with	9.3	months	(95%	CI:	5.9-12.9)	for	the	pa=ents	treated	on	a	phase	I	
trial	vs.	5.3	months	(95%	CI:	4.1-6.1)	for	those	who	were	not.	
Figure	3.	Kaplan	–	Meier	curves	of	OS	in	pa8ents	with	steroid	use	(A),	steroid	use	and	NLR	>	4	(B)	and	
steroid	 use	 and	 NLR	 <	 4	 (C).	 A:	 The	 use	 of	 steroids	 was	 associated	 with	 shorter	 overall	 survival	 in	
mul8variate	analysis	(HR	1.84,	95%	CI:	1.05-3.24,	p=0.034).	B,	C:	Median	OS	for	pa8ents	with	NLR	≥	4	on	
steroids	was	4.1	months	(SE	0.29,	95%	CI	3.29-5.42),	vs	19	months	median	OS	for	pa8ents	taking	steroids		
with	NLR	<	4	(SE	8.61	95%	CI.36-not	reached).	
